TMCnet News
RealPennies.com: Turning Pennies into dollars: (OTCBB:ISCO) International Stem Cell Corp(M2 PressWIRE Via Acquire Media NewsEdge) RDATE:17032009 Are you a public company looking for exposure? Contact RealPennies.com - 212-662-2147 For more info: http://www.realpennies.com/otc/isco International Stem Cell Corporation Receives Third $1M Tranche under a $5 Million Financing (OTCBB:ISCO) International Stem Cell Corp. International Stem Cell Corporation Receives Third $1M Tranche under a $5 Million Financing OCEANSIDE, Calif. -- International Stem Cell Corporation has received the third $1 million tranche of an anticipated private equity financing of up to $5 million to be funded over the next several months. The total amount of the financing will allow the Company to move forward with the construction of its new cGMP cell culture facility and to continue its therapeutic research, including ongoing pre-clinical trials. The money will also be allocated to fund equipment, product development and marketing requirements to increase revenues in the Company's subsidiary, Lifeline Cell Technology, which makes and sells specialty cells and growth media. ISCO is the creator and developer of a new class of stem cells that remove two of the greatest barriers to the therapeutic use of stem cells: 1) immune rejection and 2) the ethical issues that surround the use of embryonic stem cells. ISCO's technology, called 'parthenogenesis,' results in the creation of cell lines that may allow cells from a single donor to be immune-matched to hundreds of millions of people - thus reducing the dangers of immune rejection. ISCO's parthenogenetic stem cells come from unfertilized human eggs, thus avoiding ethical issues associated with embryonic stem cells. To help promote therapeutic research, ISCO makes its stem cells available to qualified researchers worldwide. To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0. For more news and information on International Stem Cell Corporation please visit www.IRGnews.com/coi/ISCO where you can find the CEO's video, a fact sheet on the company, investor presentations, and more. ABOUT INTERNATIONAL STEM CELL CORPORATION: International Stem Cell Corporation is a California biotechnology company focused on developing therapeutic and research products. ISCO's technology, Parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs. ISCO scientists have created the first Parthenogenetic homozygous stem cell line that can be a source of therapeutic cells that will minimize immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. These advancements offer the potential to create the first true 'Stem Cell Bank' and address ethical issues by eliminating the need to use or destroy fertilized embryos. ISCO also produces and markets specialized cells and growth media worldwide for therapeutic research through its subsidiary Lifeline Cell Technology. For more information, visit the ISCO website at: www.internationalstemcell.com. FORWARD-LOOKING STATEMENTS: Statements pertaining to anticipated future financial and/or operating results, future growth in research, technology, clinical development and potential joint venture and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as 'will,' 'believes,' 'plans,' 'anticipates,' 'expects,' 'estimates,') should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements. Key Words: Stem Cells, Biotechnology, Parthenogenesis Contact: International Stem Cell Corporation Kenneth C. Aldrich, Chairman, CEO 760-940-6383 [email protected] or William Adams, Chief Financial Officer 760-940-6383 [email protected] or The Investor Relations Group 212-825-3210 Investor Relations: Adam S. Holdsworth [email protected] or Media Relations: Laura Colontrelle [email protected] Source: International Stem Cell Corporation Profile for International Stem Cell Corp. International Stem Cell Corporation, a biotechnology company, focuses on the development of therapeutic and research products. The company is developing stem cells that are comparable in function to embryonic stem cells from which, cells for human transplant can be derived; techniques to cause those cells to be differentiated into the specific cell types required for transplant; and manufacturing protocols to produce these cells without contamination with animal by-products in compliance with the U.S. Food and Drug Administration requirements. Its cells could be used for the treatment of various diseases, including diabetes, liver disease, corneal disease, and retinal disease through cell tr... Detailed ISCO Company Description... LAST $0.50 USD Find out more about ISCO Safe Harbor Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties. Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on http://www.realpennies.com/start.html Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. This may contain forward-looking statements and are not guarantees of performance. Reproduction of this without written permission is prohibited. CONTACT: RealPennies.com Tel: +1 212 662 2147 e-mail: [email protected] WWW: http://www.realpennies.com ((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected])). Copyright ? 2009 M2 Communications Ltd. |